DK1268480T3 - 8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer - Google Patents

8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer

Info

Publication number
DK1268480T3
DK1268480T3 DK01940294T DK01940294T DK1268480T3 DK 1268480 T3 DK1268480 T3 DK 1268480T3 DK 01940294 T DK01940294 T DK 01940294T DK 01940294 T DK01940294 T DK 01940294T DK 1268480 T3 DK1268480 T3 DK 1268480T3
Authority
DK
Denmark
Prior art keywords
xanthine
isoquinoline
quinoline
pde5 inhibitors
derivatives
Prior art date
Application number
DK01940294T
Other languages
English (en)
Inventor
Gurdip Bhalay
Stephen Paul Collingwood
Robin Alec Fairhurst
Sylvie Felicite Gomez
Reto Naef
David Andrew Sandham
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1268480T3 publication Critical patent/DK1268480T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DK01940294T 2000-04-07 2001-04-05 8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer DK1268480T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008694.2A GB0008694D0 (en) 2000-04-07 2000-04-07 Organic compounds
PCT/EP2001/003909 WO2001077110A1 (en) 2000-04-07 2001-04-05 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors

Publications (1)

Publication Number Publication Date
DK1268480T3 true DK1268480T3 (da) 2004-03-15

Family

ID=9889516

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01940294T DK1268480T3 (da) 2000-04-07 2001-04-05 8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer

Country Status (29)

Country Link
US (1) US20030171384A1 (da)
EP (1) EP1268480B1 (da)
JP (1) JP3869725B2 (da)
KR (1) KR100526094B1 (da)
CN (1) CN1176922C (da)
AR (1) AR028531A1 (da)
AT (1) ATE253576T1 (da)
AU (2) AU7392101A (da)
BR (1) BR0109855A (da)
CA (1) CA2403514C (da)
CZ (1) CZ20023305A3 (da)
DE (1) DE60101158T2 (da)
DK (1) DK1268480T3 (da)
ES (1) ES2210169T3 (da)
GB (1) GB0008694D0 (da)
HU (1) HUP0300565A3 (da)
IL (1) IL152078A0 (da)
MX (1) MXPA02009903A (da)
MY (1) MY119238A (da)
NO (1) NO20024741D0 (da)
NZ (1) NZ521361A (da)
PE (1) PE20020228A1 (da)
PL (1) PL212407B1 (da)
PT (1) PT1268480E (da)
RU (1) RU2269529C2 (da)
SK (1) SK14282002A3 (da)
TR (1) TR200400185T4 (da)
WO (1) WO2001077110A1 (da)
ZA (1) ZA200207956B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
RU2295525C2 (ru) 2002-06-12 2007-03-20 Ф.Хоффманн-Ля Рош Аг Амидозамещенные производные ксантина, обладающие ингибирующим действием фосфоенолпируваткарбоксикиназы (фепкк), способ их получения, фармацевтическая композиция и применение
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
KR101150449B1 (ko) * 2002-08-21 2012-06-01 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
ATE385234T1 (de) * 2003-02-19 2008-02-15 Hoffmann La Roche Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren
US7148229B2 (en) 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
KR100658080B1 (ko) * 2003-08-26 2006-12-15 비오이 하이디스 테크놀로지 주식회사 백라이트 조립용 지그
TW200605893A (en) * 2004-02-12 2006-02-16 Novartis Ag Use of organic compounds
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7915288B2 (en) * 2004-05-08 2011-03-29 Novartis International Pharmaceutical Ltd. 1-aryl-4-substituted isoquinolines
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
WO2006104870A2 (en) * 2005-03-25 2006-10-05 Schering Corporation Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
CN101711153A (zh) * 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
US8841447B2 (en) * 2009-03-26 2014-09-23 Mapi Pharma Ltd. Process for the preparation of alogliptin
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8772316B2 (en) * 2011-02-18 2014-07-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014071044A1 (en) * 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558162B1 (fr) * 1984-01-17 1986-04-25 Adir Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
AU4501199A (en) * 1998-06-03 1999-12-20 Almirall Prodesfarma S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PL212407B1 (pl) 2012-09-28
CN1176922C (zh) 2004-11-24
DE60101158T2 (de) 2004-08-26
US20030171384A1 (en) 2003-09-11
IL152078A0 (en) 2003-05-29
JP2003530398A (ja) 2003-10-14
KR100526094B1 (ko) 2005-11-08
PL358205A1 (en) 2004-08-09
GB0008694D0 (en) 2000-05-31
BR0109855A (pt) 2003-06-03
HUP0300565A3 (en) 2004-10-28
PE20020228A1 (es) 2002-03-28
ES2210169T3 (es) 2004-07-01
MY119238A (en) 2005-04-30
CA2403514C (en) 2010-01-12
NO20024741L (no) 2002-10-02
AU7392101A (en) 2001-10-23
CZ20023305A3 (cs) 2003-01-15
JP3869725B2 (ja) 2007-01-17
RU2269529C2 (ru) 2006-02-10
CA2403514A1 (en) 2001-10-18
ATE253576T1 (de) 2003-11-15
AR028531A1 (es) 2003-05-14
KR20020081590A (ko) 2002-10-28
EP1268480B1 (en) 2003-11-05
ZA200207956B (en) 2003-07-16
HUP0300565A2 (hu) 2003-07-28
CN1420887A (zh) 2003-05-28
RU2002129557A (ru) 2004-03-27
PT1268480E (pt) 2004-03-31
MXPA02009903A (es) 2003-03-27
NO20024741D0 (no) 2002-10-02
SK14282002A3 (sk) 2003-04-01
DE60101158D1 (en) 2003-12-11
EP1268480A1 (en) 2003-01-02
NZ521361A (en) 2004-05-28
WO2001077110A1 (en) 2001-10-18
AU2001273921B2 (en) 2005-05-05
TR200400185T4 (tr) 2004-03-22

Similar Documents

Publication Publication Date Title
DK1268480T3 (da) 8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer
ATE433451T1 (de) Xanthin-phosphodiesteras-v-inhibitoren
NO20023713D0 (no) 2-benzotiazolyl-urea-derivater samt anvendelse derav som proteinkinaseinhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
DK1289985T3 (da) Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
DE60119492D1 (de) Purinderivate
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
DK1650203T3 (da) Quinolinonderivater som tyrosinkinaseinhibitorer
ATE267836T1 (de) Purinderivate
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
ATE372988T1 (de) Pyrimidin-derivate
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
DK1337527T3 (da) Indolylmaleinimidderivater som proteinkinase C-inhibitorer
EE200300085A (et) Pürasooli derivaadid ja nende kasutamine proteiini kinaasi inhibiitoritena
EE200300243A (et) Püridiinasendatud pürasolopüridiini derivaadid
DE60106252D1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20021959D0 (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
ATE390425T1 (de) Xanthin-phosphodiesterase-v-hemmer polymorphe
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
NO20025884L (no) 2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate